VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
12 mars 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq:VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation...
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
23 déc. 2017 16h00 HE
|
Summit Therapeutics plc
Positions Summit as a Leader in Research & Development of New Classes of AntibioticsEnhances Summit’s Broader Business in Rare and Infectious DiseasesSupports Mission to Discover and Develop...
Molecular Diagnostics Market worth over $12.5 billion by 2024: Global Market Insights, Inc.
11 déc. 2017 07h00 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Global Molecular Diagnostics Market is poised to surpass USD 12.5 billion by 2024; according to a new research report by Global Market...
BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week
18 oct. 2017 13h33 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J. and BOSTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- (BIOAEGIS THERAPEUTICS)BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN)...
BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia
13 oct. 2017 10h00 HE
|
BioAegis Therapeutics
BOSTON and MORRISTOWN, N.J., Oct. 13, 2017 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate...
Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
11 sept. 2017 07h00 HE
|
Summit Therapeutics PLC
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for...
Genome Editing Market to grow at 14% CAGR and exceed $7.5 billion by 2024: Global Market Insights, Inc.
10 août 2017 07h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, Aug. 10, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Gene Editing Market By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), Meganucleases, TALENS), By...
Esoteric Testing Market worth over $35 billion by 2024: Global Market Insights, Inc.
24 juil. 2017 05h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, July 24, 2017 (GLOBE NEWSWIRE) -- The Industry Growth report “Esoteric Testing Market By Test Type (Endocrinology, Infectious Disease & Immunology, Oncology,...
Molecular Diagnostics Market to hit $10bn by 2023: Global Market Insights Inc.
20 mars 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, March 20, 2017 (GLOBE NEWSWIRE) -- The trends outlook report “Molecular Diagnostics Market Size By Infectious Disease (Flu, Tuberculosis, Meningitis, RSV Virus, Hepatitis B,...
Elsevier Updates Infectious Diseases Reference Aimed at Controlling and Preventing Neglected and Emerging Worldwide Diseases
27 févr. 2017 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - February 27, 2017) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of an...